Not Signed In - FDA Approves BYETTA® (exenatide) Injection For Expanded Combination Use
Thu, 28 Dec 2006 08:00 AM EST
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved BYETTA® (exenatide) injection as an add-on therapy to improve blood sugar control in people with type 2 diabetes who have not achieved adequate control on a thiazolidinedione (TZD). [click link for full article] ...
Related Topics
- Combination Vaccines
- Combination Diet
- Dicyclomine Injection
- Cortisone Injection
- Tacrolimus ointment
- Mammography
- Dimenhydrinate Injection
- Calcitonin Salmon Injection
- Bismuth Subsalicylate, Metronidazole, and Tetracycline Combination
- Sulfamethoxazole and Trimethoprim Injection
- Carcinogens
- Dexamethasone Injection
- Progesterone Injection
- Zidovudine Injection
- Pimecrolimus Cream 1%
- Ketorolac Injection
- Dietary Guidelines
- Ribavirin and Interferon alfa-2b, recombinant
- Heparin Injection
- Caffeine Injection
email this page
print this page
bookmark this page
feedback on this page
